138 related articles for article (PubMed ID: 33015101)
1. Wnt Inhibitors and Bone Turnover Markers in Patients With Polymyalgia Rheumatica and Acute Effects of Glucocorticoid Treatment.
Fassio A; Adami G; Idolazzi L; Giollo A; Viapiana O; Vantaggiato E; Benini C; Rossini M; Dejaco C; Gatti D
Front Med (Lausanne); 2020; 7():551. PubMed ID: 33015101
[No Abstract] [Full Text] [Related]
2. In psoriatic arthritis Dkk-1 and PTH are lower than in rheumatoid arthritis and healthy controls.
Fassio A; Idolazzi L; Viapiana O; Benini C; Vantaggiato E; Bertoldo F; Rossini M; Gatti D
Clin Rheumatol; 2017 Oct; 36(10):2377-2381. PubMed ID: 28634697
[TBL] [Abstract][Full Text] [Related]
3. Effect of glucocorticoid treatment on Wnt signalling antagonists (sclerostin and Dkk-1) and their relationship with bone turnover.
Gifre L; Ruiz-Gaspà S; Monegal A; Nomdedeu B; Filella X; Guañabens N; Peris P
Bone; 2013 Nov; 57(1):272-6. PubMed ID: 23981659
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of tumor necrosis factor-alpha (TNF-alpha) in patients with early rheumatoid arthritis results in acute changes of bone modulators.
Fassio A; Adami G; Gatti D; Orsolini G; Giollo A; Idolazzi L; Benini C; Vantaggiato E; Rossini M; Viapiana O
Int Immunopharmacol; 2019 Feb; 67():487-489. PubMed ID: 30599401
[TBL] [Abstract][Full Text] [Related]
5. Acute Effects of Glucocorticoid Treatment, TNFα or IL-6R Blockade on Bone Turnover Markers and Wnt Inhibitors in Early Rheumatoid Arthritis: A Pilot Study.
Fassio A; Adami G; Giollo A; Viapiana O; Malavolta N; Saviola G; Bortolotti R; Idolazzi L; Bertoldo F; Rossini M; Gatti D
Calcif Tissue Int; 2020 Apr; 106(4):371-377. PubMed ID: 31897527
[TBL] [Abstract][Full Text] [Related]
6. Tocilizumab controls bone turnover in early polymyalgia rheumatica.
Carvajal Alegria G; Garrigues F; Bettacchioli E; Loeuille D; Saraux A; Cornec D; Devauchelle-Pensec V; Renaudineau Y
Joint Bone Spine; 2021 May; 88(3):105117. PubMed ID: 33301930
[TBL] [Abstract][Full Text] [Related]
7. Changes in Dkk-1, sclerostin, and RANKL serum levels following discontinuation of long-term denosumab treatment in postmenopausal women.
Fassio A; Adami G; Benini C; Vantaggiato E; Saag KG; Giollo A; Lippolis I; Viapiana O; Idolazzi L; Orsolini G; Rossini M; Gatti D
Bone; 2019 Jun; 123():191-195. PubMed ID: 30910600
[TBL] [Abstract][Full Text] [Related]
8. Glucocorticoid therapy causes contradictory changes of serum Wnt signaling-related molecules in systemic autoimmune diseases.
Kawazoe M; Kaneko K; Shikano K; Kusunoki N; Nanki T; Kawai S
Clin Rheumatol; 2018 Aug; 37(8):2169-2178. PubMed ID: 28551822
[TBL] [Abstract][Full Text] [Related]
9. Secukinumab produces a quick increase in WNT signalling antagonists in patients with psoriatic arthritis.
Fassio A; Gatti D; Rossini M; Idolazzi L; Giollo A; Adami G; Gisondi P; Girolomoni G; Viapiana O
Clin Exp Rheumatol; 2019; 37(1):133-136. PubMed ID: 30418122
[TBL] [Abstract][Full Text] [Related]
10. Effect of recent spinal cord injury on wnt signaling antagonists (sclerostin and dkk-1) and their relationship with bone loss. A 12-month prospective study.
Gifre L; Vidal J; Carrasco JL; Filella X; Ruiz-Gaspà S; Muxi A; Portell E; Monegal A; Guañabens N; Peris P
J Bone Miner Res; 2015 Jun; 30(6):1014-21. PubMed ID: 25484108
[TBL] [Abstract][Full Text] [Related]
11. Adrenal gland hypofunction in active polymyalgia rheumatica. effect of glucocorticoid treatment on adrenal hormones and interleukin 6.
Cutolo M; Straub RH; Foppiani L; Prete C; Pulsatelli L; Sulli A; Boiardi L; Macchioni P; Giusti M; Pizzorni C; Seriolo B; Salvarani C
J Rheumatol; 2002 Apr; 29(4):748-56. PubMed ID: 11950017
[TBL] [Abstract][Full Text] [Related]
12. Regulation of sclerostin in glucocorticoid-induced osteoporosis (GIO) in mice and humans.
Thiele S; Hannemann A; Winzer M; Baschant U; Weidner H; Nauck M; Thakker RV; Bornhäuser M; Hofbauer LC; Rauner M
Endocr Connect; 2019 Jul; 8(7):923-934. PubMed ID: 31234141
[TBL] [Abstract][Full Text] [Related]
13. Leukocyte Dynamics Reveal a Persistent Myeloid Dominance in Giant Cell Arteritis and Polymyalgia Rheumatica.
van Sleen Y; Graver JC; Abdulahad WH; van der Geest KSM; Boots AMH; Sandovici M; Brouwer E
Front Immunol; 2019; 10():1981. PubMed ID: 31507597
[TBL] [Abstract][Full Text] [Related]
14. Long-term glucocorticoid treatment in patients with polymyalgia rheumatica, giant cell arteritis, or both diseases: results from a national rheumatology database.
Albrecht K; Huscher D; Buttgereit F; Aringer M; Hoese G; Ochs W; Thiele K; Zink A
Rheumatol Int; 2018 Apr; 38(4):569-577. PubMed ID: 29124397
[TBL] [Abstract][Full Text] [Related]
15. Bone turnover in untreated polymyalgia rheumatica.
Barnes TC; Daroszewska A; Fraser WD; Bucknall RC
Rheumatology (Oxford); 2004 Apr; 43(4):486-90. PubMed ID: 14722347
[TBL] [Abstract][Full Text] [Related]
16. The key role of proinflammatory cytokines, matrix proteins, RANKL/OPG and Wnt/β-catenin in bone healing of hip arthroplasty patients.
Cassuto J; Folestad A; Göthlin J; Malchau H; Kärrholm J
Bone; 2018 Feb; 107():66-77. PubMed ID: 29129760
[TBL] [Abstract][Full Text] [Related]
17. Association of serum Dkk-1 levels with β-catenin in patients with postmenopausal osteoporosis.
Tian J; Xu XJ; Shen L; Yang YP; Zhu R; Shuai B; Zhu XW; Li CG; Ma C; Lv L
J Huazhong Univ Sci Technolog Med Sci; 2015 Apr; 35(2):212-218. PubMed ID: 25877354
[TBL] [Abstract][Full Text] [Related]
18. Effects of inflammation and treatment on bone turnover and bone mass in polymyalgia rheumatica.
Dolan AL; Moniz C; Dasgupta B; Li F; Mackintosh C; Todd P; Corrigall V; Panayi GS
Arthritis Rheum; 1997 Nov; 40(11):2022-9. PubMed ID: 9365092
[TBL] [Abstract][Full Text] [Related]
19. Polymyalgia rheumatica: inflammation suppression with low dose of methylprednisolone or modified-release prednisone.
Benucci M; Olivito B; Manfredi M; Meacci F; Infantino M; Li Gobbi F; Sarzi-Puttini P; Marcassa C; Atzeni F
Eur Rev Med Pharmacol Sci; 2015; 19(5):745-51. PubMed ID: 25807425
[TBL] [Abstract][Full Text] [Related]
20. Comparative effect of zoledronic acid versus denosumab on serum sclerostin and dickkopf-1 levels of naive postmenopausal women with low bone mass: a randomized, head-to-head clinical trial.
Anastasilakis AD; Polyzos SA; Gkiomisi A; Bisbinas I; Gerou S; Makras P
J Clin Endocrinol Metab; 2013 Aug; 98(8):3206-12. PubMed ID: 23788684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
